Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Parkinson's patients try antioxidant supplements to boost brain health

NCT ID NCT02445651

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether nutritional supplements, specifically N-acetyl cysteine (NAC) given orally and intravenously, could support brain function in people with Parkinson's disease. The researchers measured dopamine activity and markers of inflammation in the brain using special scans. 51 participants were randomly assigned to receive NAC, standard care, or other oral supplements, though the oral supplement group was later dropped from analysis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Mar 2014

Finished

Aug 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical Diagnosis of Parkinson's disease * Subject is between 30 - 80 years of age * Subject has a Hoehn and Yahr score of I - II inclusive * Subject is on stable or on antiparkinsonian medication for at least a month * Women of Childbearing potential will confirm a negative pregnancy test Exclusion Criteria: * Subject is allergic to iodine, cobalt, or any of the supplements that will be given in the study * Subject has had previous brain surgery * Subject has a score of 25 or less on Mini-Mental Status examination * Subject is wheelchair-bound or bed-ridden; non ambulatory * Subject has intracranial abnormalities that may complicate interpretation of the brain scans(e.g., stroke, tumor, vascular abnormality affecting the target area) * Subject has a history of head trauma with loss of consciousness greater than 48 hours * Subject has any medical disorder or physical condition that could reasonably be expected to interfere with the assessment of parkinsonian syndrome symptoms, or with any of the study assessments including the SPECT imaging. * Subject has evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study * Subject has a current alcohol or drug abuse * Subject is pregnant or lactating * Subject is enrolled in active clinical (drug or device) trial within the prior 30 days * Subject is pending surgery during the course of the study * History of very low blood pressure * History of thrombocytopenia or clotting disorders * Cancer patients receiving active chemotherapy * History of active gallstone problems or a bile duct obstruction * History of uncontrolled diabetes, asthma, gastroesophageal reflex disease, or thyroid * History of severe kidney disease (if the patient reports this problem, a serum creatinine will be checked to assess GFR; if it is less than 30, the patient will be excluded) * History of Leber's disease, a hereditary eye disease * History of uncontrolled hypercalcemia * History of active sarcoidosis, histoplasmosis, or lymphoma * Patients taking medication that might interact with the supplements involved in this study will be evaluated on a case-by-case basis by PI study physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.